Syneos Health (SYNH) Earns Buy Rating from Analysts at UBS Group
Equities research analysts at UBS Group began coverage on shares of Syneos Health (NASDAQ:SYNH) in a note issued to investors on Tuesday, The Fly reports. The firm set a “buy” rating on the stock.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.